Amar & Yashasvi is a bio-pharma startup envisaged to manufacture import substitute active pharma ingredients (APIs) by leveraging its collaborations with the in-house research team and world-class research teams from India's most prestigious IITs. India imports enormous quantities of APIs and its intermediates from China to match domestic demands. These include biotechnology-based molecules. Chinese firms manufacturing bio-fermented molecules have mastered bio-fermentation techniques in the last decade. Many of those firms use wild-type microorganism strains in fermentation to yield APIs. These strains often lack necessary proteins and nutrients and are low yielding. They need tedious upstream and downstream processes. However, the economies of scale, ease of process design and market dominance negate low productivity and exhausting upstream-downstream processes of wild-type stains. Being a technology startup, we may not compete with the economies of scale of the Chinese manufacturers in the initial phase of our product manufacturing with their production approach. So, we propose an alternative; a single-recombinant-organism-based method to produce APIs. This method is an advan

Manufacture of chemicals and chemical products

Source: Ministry of Corporate Affairs company master (open data). Capital figures are as-of the 2021 registry snapshot, not live.